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Abstract
Background. Acute kidney injury (AKI) occurs in up to 30% of pediatric intensive care unit (PICU) patients 
and is associated with a high mortality rate.
Objectives. The objective of the study was to evaluate factors associated with the outcome and to identify 
the prognostic factors in children receiving continuous renal replacement therapy (CRRT).
Material and methods. This was a retrospective, single-center study, including 46 patients.
Results. Logistic regression analysis demonstrated significant effects on patient survival exerted by the 
percentage of fluid overload (FO%) (odds ratio (OR): 1.030; p = 0.044). In the group of patients with 
FO% <25%, the mortality was 33.3%, and in the FO% ≥25% group, the mortality was 67.9% (p < 0.001). 
The probability of death without multi-organ failure (MOF) was 13%, while with MOF it was 74%. There 
was no difference in the duration of hospitalization between the CRRT patients (mean: 21.9 days) and the 
general population of children hospitalized in PICU in the same period (n = 3,255; mean: 25.4 days); however, 
a significant difference was noted in mortality between the 2 groups of patients (54% vs 6.5%; p < 0.001).
Conclusions. The mortality of PICU CRRT patients is more than 8-fold higher than the mortality of the 
total PICU population. Coexisting MOF increases the mortality almost 6 times. The mortality of children with 
FO% ≥25% was more than 2-fold higher than the mortality of children with FO% <25%.
Key words: acute kidney injury, survival, anticoagulation, pediatric intensive care unit, continuous renal 
replacement therapy
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Introduction
Acute kidney injury (AKI) is observed in up to 30% of chil-
dren admitted to pediatric intensive care units (PICUs) and 
is associated with a mortality rate of up to 50%.1–3 There 
is evidence that the epidemiology of pediatric AKI has 
changed over the past few decades and that primary renal 
diseases are currently no longer the most common causes 
of AKI.4 Nowadays, the most frequent causes of AKI in de-
veloped countries are acute tubular necrosis, nephrotoxic 
medications, oncological diseases, septic shock, and their 
common consequence – multi-organ-failure (MOF).5 Over 
the past 2 decades, in many developed countries, continu-
ous renal replacement therapy (CRRT) has become the 
most widely used renal support modality in critically ill 
children.6 It eliminates the need for fluid restriction and 
allows for the provision of medications, blood products 
and nutrition in critically ill children.7
Despite the increasing use of CRRT, AKI is associated 
with an  increased risk of mortality in critically ill pa-
tients.8,9 Although formal and clearly defined indications 
for CRRT use are lacking, it is mostly employed for indi-
vidual AKI and AKI associated with fluid overload (FO), 
MOF and sepsis.10 Furthermore, there are still not many 
published reports addressing CRRT in PICUs.6
The main objective of the present study was to evaluate 
the clinical course, to analyze factors associated with the 
outcome and to identify prognostic factors in critically ill 
children receiving CRRT.
Material and methods
This was a retrospective, single-center, chart review 
study, including 46 patients receiving CRRT, who had been 
admitted to the PICU in the Department of Anesthesiology 
and Intensive Care, Institute of Pediatrics, Jagiellonian 
University Medical College, Kraków, Poland, between Jan-
uary 2009 and December 2016. This study was approved 
by the Bioethical Committee of Cracow Medical Chamber 
(OIL/KBL/4/2017).
Initiation, prescription and general CRRT management 
occurred under the guidance of the attending intensivist 
and consulting nephrologist. The primary indications for 
the initiation of CRRT were categorized as AKI, FO or MOF. 
Fluid overload percentage (FO%) was determined using the 
PICU admission weight in kilograms as the baseline weight 
for comparison. The FO% was defined using the method 
described by Goldstein et al. ([fluid in – fluid out]/[inten-
sive care unit admission weight] × 100%), and fluid in (or 
out) was considered to be the amount of fluid from admis-
sion to PICU to CRRT initiation.11 Acute kidney injury was 
determined by the pediatric-modified Risk, Injury, Failure, 
Loss of kidney function, and End-stage kidney disease score 
(RIFLE, modified into p-RIFLE).2 Multi-organ failure was 
defined as the presence of at least 2 organs involved at any 
time on admission to PICU.12 Sepsis was defined using the 
criteria of the International Consensus Conference on Pe-
diatric Sepsis.12
A Prismaflex dialysis machine (Gambro, Barcelona, 
Spain) was used for CRRT in all the patients. Dual lu-
men catheters were used depending on the age, weight 
and morphology of the child, using the same criteria for 
the patients treated with regional citrate anticoagulation 
(RCA) and heparin anticoagulation (Hep-ACG).8,13 Hol-
low fiber hemofilters were used depending on the body 
weight of the patient, according to the guidelines of the 
manufacturer.14
In  all the Hep-ACG cases, predilutional continuous 
veno-venous hemodiafiltration (CVVHDF) was em-
ployed and unfractionated heparin (Hep) was used. In the 
Hep-ACG protocol, a Hep bolus was administered during 
the connection along with a subsequent continuous Hep 
infusion to achieve a post-filter activated clotting time 
(ACT) between 180 and 240 s. The ACT value was checked 
on average every 2 h within the first 12 h of CRRT, and 
then every 4–6 h.
The RCA procedure was conducted according to the 
guidelines from the study by Tolwani et al. and from the 
Prismaflex operator's manual.14,15 An initial citrate con-
centration of 3.0 mmol/L was used for a target post-filter 
ionized calcium level of 0.25–0.50 mmol/L. The citrate 
effect was neutralized using a continuous calcium infu-
sion of 10% calcium gluconate (or 5% in children weigh-
ing <15 kg) to maintain ionized calcium blood levels be-
tween 1.0 and 1.2 mmol/L.15,16 Samples were taken every 
hour for the first 4 h and every 6–8 h afterwards. Total 
calcium levels were also checked at least once daily. Citrate 
accumulation was avoided by monitoring the patient's pH 
status and by total calcium/ionic calcium index (CaT/CaI) 
being maintained ≤2.5. 
Regarding the CRRT solutions for Hep-ACG, Hemosol, 
or PrismaSol 2 (Gambro) as a dialyzate and Phoxilium 
(Gambro) or PrismaSol 2 as a predilutional substitute were 
used; whereas for RCA, the citrate solution Prismocitrate 
18/0 (Gambro) was administered in a pre-blood pump 
(PBP), the dialyzate normocarbonate solution PrismOcal 
B22 (Gambro) was used as a calcium-free dialysis solu-
tion, and the low-flow post-filter infusion of PrismaSol 2 
or Phoxillum was employed as a postdilutional substitute 
to avoid clotting in the deaeration chamber return line.
In both techniques, the dialyzate and substitution flow 
rates were initially programmed to achieve a dialysis dose 
of at least 35 mL/kg/h and were subsequently adjusted 
in an ongoing manner to meet the patients’ needs. None 
of the filters were used for longer than 72 h. The blood 
flow rates (BFR) were determined according to the pa-
tients’ body mass and were monitored by the pressure at 
the access sites.15
Dual lumen catheters were individually adapted to the 
child’s morphology and body weight according to the lit-
erature recommendations.8,13 The implantation sites of the 
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dual lumen catheters included the left femoral vein in 19 
cases (41.3%), the right femoral vein in 13 cases (28.3%) and 
the right internal jugular vein in 14 cases (30.4%).
The collected data addressed the patients’ demographics, 
underlying disease, detailed CRRT parameters, and the mode 
and dose of the applied anticoagulation (ACG) method.
Statistical analysis
The  distribution of  polytomous variables was de-
scribed employing the mean value, standard deviation 
(SD), median value, and interquartile range (IQR). To 
compare the distributions, Student’s t-test was used, 
providing the Kolmogorov-Smirnov (KS) test yielded 
a positive result for conformity of the empirical dis-
tribution and Gaussian distribution. In  case of  a  lack 
of such conformity, the Wilcoxon rank-sum test (equiv-
alent to the Mann-Whitney U test) was employed; this 
fact was indicated by marking the appropriate p-value 
with an  asterisk (*). The  sample sizes were compared 
by means of the χ2 test; in the cases with low predicted 
frequencies, Yates’s modification was employed, which 
was indicated by marking the appropriate p-values with 
2 asterisks (**). The effect of FO% on the cumulative sur-
vival probability of the patients was analyzed employing 
the Kaplan-Meier curves and the Mantel-Cox test. Ad-
ditionally, the univariate and multivariate analyses of sig-
nificant parameters were carried out depending on ACG 
and the outcome. In addition, the univariable and mul-
tivariable logistic regression analyses were performed, 
identifying the parameters showing a significant odds ra-
tio (OR) and describing the effect on the outcome. When 
only dichotomous input variables were considered, the 
OR was computed directly from the contingency table 
analysis. It should be emphasized that depending on the 
employed mode of analysis, the numerical assessment 
of the effect of a given parameter on the outcome was 
achieved in the form of probability of death (mortality) or 
OR of death (mortality OR). In all tests, the significance 
threshold was assumed to be 0.05, with the exception of the 
KS test, where a value of 0.1 was assumed to be significant. 
The STATISTICA v. 12 (StatSoft Inc., Tulsa, USA) and 
MATLAB v. 2015a (Mathworks, Natick, USA) packages 
were used for all calculations and for creating the graphs.
Results
The number of children requiring CRRT in particular 
years was as follows: in 2009 – 6 patients; 2010 – 3; 2011 
– 7; 2012 – 4; 2013 – 6; 2014 – 5; 2015 – 5; and in 2016 – 10. 
As RCA has been used in our center since 2015, 4 patients 
in 2015 and 10 patients in 2016 were treated with this mode 
of ACG. The Hep-ACG was applied in all other cases.
A detailed characteristics of  the study population 
is included in Tables 1 and 2. The main diagnoses in the 
studied population were as follows: 1. oncological diseases 
– 20 children (43.5%), including acute lymphoblastic leu-
kemia – 11 (8 after bone marrow transplantation (BMT)), 
lymphoma – 3, solid tumors – 3, and acute myeloid leuke-
mia after BMT – 3; 2. hematological diseases – 6 children 
(13%), including aplastic anemia after BMT – 3, severe 
combined immunodeficiency after BMT – 2 and hemo-
phagocytic syndromes after BMT – 1; 3. nephrological 
diseases – 11 children (24%), including chronic kidney 
disease (CKD) exacerbation – 4, chronic dialysis com-
plications – 3, rapid progressive glomerulonephritis – 1, 
hemolytic uremic syndrome – 2, and tubulointerstitial 
nephritis – 1; 4. sepsis – 3 children (6.5%), including Neis-
seria meningitidis – 2 and Streptococcus spp. – 1; 5. burns 
– 2 children (4.3%); 6. cardiovascular diseases – 2 children 
(4.3%); 7. rheumatic disease (systemic lupus erythemato-
sus) – 1 child (2.2%); and 8. gastroenterological diseases 
– 1 child (2.2%).
There were no statistically significant differences in the 
ratio of the main diagnoses, neither between Hep-ACG and 
RCA, nor between deceased and surviving patients (apart 
from nephrological diagnoses in the case of deceased vs 
surviving patients: 1 vs 10; p = 0.001).
While comparing the sample size in children dialyzed 
with Hep-ACG vs RCA, no statistically significant dif-
ferences were noted in gender, body mass, body height, 
or outcome, which means that the studied populations 
were mutually equivalent and relevantly representative for 
the current study. The patients treated with RCA demon-
strated longer hospitalization in PICU, were younger, and, 
in view of the additional citrate flow, they received a higher 
dialysis dose in total than the children treated with Hep-
ACG. In turn, when compared to the RCA group, the chil-
dren treated with Hep-ACG were characterized by a more 
severe clinical status (which was evident in a higher num-
ber of vasopressor medications (VPS) at CRRT initiation 
and a higher absolute percentage of days with VPS admin-
istration during their PICU stay), required mechanical 
ventilatory support extending over a longer proportion 
of their PICU hospitalization and their urine output (UO) 
at the time of CRRT initiation was lower.
As shown in Tables 2 and 3, 46% of the patients from 
the study population survived. There were no significant 
differences between the survivors and non-survivors with 
respect to age, weight, height, gender, number of days 
spent in  PICU, estimated glomerular filtration rate 
(eGFR) value, urea concentration, total protein, albumin 
concentration at the start of CRRT, day of CRRT initia-
tion, number of hours of CRRT per patient, dialysis dose 
per patient, ultrafiltration rate (UFR) value per patient, 
or ACT value.
On the other hand, as shown in Table 2, the surviving 
children were subjected to CRRT mainly for AKI or FO% 
(as the immediate causes of CRRT initiation), required 
less intensive mechanical ventilatory support during their 
hospitalization in PICU, had fewer VPS at CRRT initiation, 
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had a lower absolute percentage of days with VPS admin-
istration during their PICU stay, and had lower values 
of inflammatory marker (C-reactive protein (CRP)), but 
they maintained a significantly higher diuresis value at 
the time of CRRT initiation, which resulted in their mean 
degree of overhydration being 1.9 times lower on average. 
If the positive blood culture was not associated with sepsis, 
or with AKI and/or FO%, it also did not affect mortal-
ity in these patients. The only factor that was associated 
with a lower mortality was nephrological primary disease. 
Multi-organ failure occurred in 92% of the deceased chil-
dren and it proved that the probability of death without 
MOF amounted to 13%, while the probability of death with 
MOF was 74%, thus being 5.7 times higher (mortality OR: 
18.7; p < 0.001).
As shown in Table 2, FO% showed significant differences 
between the surviving and deceased children. In the group 
of children with FO% <25% (n = 18), mortality amount-
ed to 33.3% (n = 6), while in the group of children with 
FO% ≥25% (n = 28), mortality was more than 2-fold higher, 
amounting to 67.9% (n = 19, p < 0.001). Also, the analysis 
of the Kaplan-Meier curves (Fig. 1) showed that the surviv-
al outcomes worsened with FO% ≥25% at CRRT initiation.
The univariable logistic regression analysis demonstrat-
ed that significant effects on patient survival were exerted 
by FO% (OR: 1.030; confidence interval (CI) 95%: 1.001–1.059; 
p  =  0.044), CRP value at CRRT initiation (OR: 1.078; 
CI 95%: 1.019–1.142; p = 0.009) and percentage of days 
with mechanical ventilatory support (OR: 1.068; CI 95%: 
1.026–1.112; p = 0.001). This denoted that each 1% increase 
Table 1. Clinical characteristics of children treated with heparin anticoagulation (Hep-ACG) and regional citrate anticoagulation (RCA)
Variable Hep-ACG, n = 32 (69.6%)n [%]
RCA, n = 14 (30.4%)
n [%] p-value
Total, n = 46
n [%]
Surviving/deceased 12 (37.5)/20 (62.5) 9 (64.3)/5 (35.7) NS 21 (45.6)/25 (54.5)
Males/females 16/16 11/3 NS 27/19
Patients with MOF as the main reason for CRRT 
implementation
24 7 NS** 31
Patients with AKI as the main reason for CRRT 
implementation
5 2 NS** 7
Patients with FO% as the main reason for CRRT 
implementation
3 5 NS** 8
Patients with mechanical ventilation at CRRT 
initiation 
27 (84.4) 8 (57.1) NS** 35 (76.1)
Days with VPS administration during PICU stay 406 (81.5) 273 (53.4) <0.001 679 (67.3)
Days with diuretic administration during PICU stay 336 (67.5) 282 (55.2) <0.001 618 (61.2)
CRRT sessions, clotted/non-clotted 27 (24.1)/85 (75.9) 34 (31.5)/74 (68.5) NS 61 (27.7)/159 (72.3)
Number of hours of CRRT sessions,  
clotted/non-clotted
516 (10)/4,666 (90); 
5,182 (48.6)
882 (16.1)/4,599 (83.9); 
5,481 (51.4)
<0.001
1,398 (13.1)/9,265 (86.9); 
10,663
Variable mean ±SD/median (IQR) mean ±SD/median (IQR) p-value mean ±SD/median (IQR)
Age [years] 10.5 ±5.4/11.7 (10.2) 6.7 ±6.8/3.8 (12.8) 0.046 9.3 ±6.0/10.3 (11.4)
Body mass [kg] 36.3 ±20.3/31.5 (31.6) 26.8 ±22.6/16.3 (35.6) NS 33.4 ±21.2/29.5 (34.6)
Body height [cm] 133.9 ±31.0/137.0 (58.5) 111.6 ±43.6/108.5 (84.0) NS 127.1 ±36.4/134.5 (67.0)
Number of days in PICU/patient 15.6 ±12.2/12.5 (17.0) 36.5 ±26.1/32.5 (52.0) 0.001 21.9 ±19.9/17.5 (27.0)
Percentage of days of mechanical ventilation 77.7 ±37.1/100.0 (40.0) 49.3 ±43.1/58.5 (100.0)   0.021* 69.0 ±40.7/100.0 (68.0)
Number of VPS at CRRT initiation 1.34 ±0.90/1.00 (1.00) 0.71 ±0.73/1.00 (1.00) 0.026 1.15 ±0.89/1.00 (2.00)
CRP [mg/L] at CRRT initiation 189 ±144/187 (229) 132 ±110/116 (149) NS 172 ±136/151 (215)
Total protein [g/L] at CRRT initiation 51.4 ±10.7/51.5 (14.1) 54.5 ±12.5/56.2 (9.7) NS 52.4 ±11.2/53.1 (15.1)
Albumin [g/L] at CRRT initiation 26.6 ±5.9/26.0 (7.8) 31.3 ±9.6/33.4 (10.1) NS 28.1 ±7.4/28.0 (11.2)
eGFR [mL/min/1.73 m2] at CRRT initiation 37.1 ±23.9/33.2 (27.9) 42.4 ±21.6/44.3 (29.1) NS 38.7 ±23.1/34.7 (32.7)
Urea [mmol/L] at CRRT initiation 25.1 ±14.4/25.2 (24.0) 21.5 ±16.7/16.1 (8.8) NS 24.0 ±15.0/20.1 (20.4)
UO [mL/kg/h] at CRRT initiation 0.75 ±0.71/0.45 (1.25) 1.54 ±1.41/1.10 (2.10) 0.014 0.99 ±1.03/0.65 (1.30)
FO% at CRRT initiation 36.7 ±32.8/26.0 (32.8) 32.6 ±29.7/29.8 (30.0) NS 35.5 ±31.6/27.3 (32.5)
Day of CRRT initiation 5.2 ±5.3/2.5 (8.0) 6.8 ±9.9/1.5 (5.0) NS* 5.7 ±6.9/2.0 (8.0)
Dialysis dose: QD+QS (+QC) [mL/h/kg]/patient 50.7 ±16.0/48.0 (18.6) 68.2 ±26.4/63.6 (35.7)  <0.001* 59.6 ±23.6/55.0 (31.9)
* Wilcoxon rank-sum test; ** Yates’s modification of the χ2 test; AKI – acute kidney injury; CRP – C-reactive protein; CRRT – continuous renal replacement 
therapy; eGFR – estimated glomerular filtration rate; FO% – fluid overload percentage; Hep-ACG – heparin anticoagulation; MOF – multi-organ failure;  
PICU – pediatric intensive care unit; QC – citrate flow rate; QD – dialyzate flow rate; QS – supplement flow rate; RCA – regional citrate anticoagulation; 
UO – urine output; VPS – vasopressors; SD – standard deviation; IQR – interquartile range; NS – not significant.
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in FO% increased the odds of death by 3%, each 10 mg/L 
increase in CRP value increased the odds of death by 7.8% 
and each 1% increase in the percentage of mechanical ven-
tilation increased the odds of death by 6.8%. In the case 
of the other parameters analyzed, including the volume 
of UO, eGFR, number of days spent in PICU, and number 
of hours of CRRT usage, no significant effect on patient 
survival was demonstrated.
The multivariable logistic regression for 2 input vari-
ables, CRP (OR: 1.098; CI 95%: 1.024–1.178; p = 0.009) 
and UO (OR: 0.404; CI 95%: 0.163–1.000; p = 0.050), indi-
cated that with simultaneous consideration of both factors, 
each 10 mg/L increase in CRP with a constant UO value 
caused an increase in the odds of death by 9.8%, whereas 
each 1 mL/kg/h increase in UO with a constant CRP value 
caused a decrease in the odds of death by 59.6%.
Heparin anticoagulation was used significantly more 
frequently and for significantly longer periods in the de-
ceased children, as compared to the group of survivors 
(Table 3). As shown in Table 3, the mortality for Hep-ACG 
was 2.3 times higher than the mortality for RCA (0.66 vs 
0.29), while the mortality OR demonstrated 4.8 times high-
er odds of death with the use of Hep-ACG vs RCA (the odds 
of death for a Hep-ACG and RCA patient were 21/11 = 1.91 
Table 2. Univariate analysis of clinical factors associated with mortality in the studied population
Variable Deceased, n = 25 (54%)n [%]
Surviving, n = 21 (46%)
n [%] p-value
Total, n = 46
n [%]
Males/females 15/10 12/9 NS 27/19
Main reason of CRRT initiation – MOF 23 8 <0.001 31
Main reason of CRRT initiation – AKI 0 7       0.006** 7
Main reason of CRRT initiation – FO% 0 8      0.003** 8
Patients with mechanical ventilation 
– SIMV
20 9  0.009 29
Patients with mechanical ventilation 
– oscillation 
5 3    NS** 8
Patients intubated on the day of CRRT 
initiation 
24 11 <0.001 33
Patients with positive blood culture 
during PICU stay 
12 5 NS 17
Patients on diuretics on the day of CRRT 
initiation 
19 14 NS 33
Days with VPS administration during 
PICU stay
425 (83.3) 254 (50.9) <0.001 679 (67.2)
Days with diuretics administration 
during PICU stay
368 (72.2) 250 (50.0) <0.001 618 (61.2)
Variable mean ±SD/median (IQR) mean ±SD/median (IQR) p-value mean ±SD/median (IQR)
Age [years] 9.9 ±6.0/10.5 (12.1) 8.7 ±6.0/8.3 (11.6) NS 9.3 ±6.0/10.3 (11.4)
Body mass [kg] 36.2 ±21.8/32.0 (34.3) 30.2 ±21.8/25.0 (34.3) NS 33.4 ±21.2/29.5 (34.6)
Body length [cm] 132.4 ±35.7/138.0 (67.8) 120.9 ±35.7/127.5 (75.1) NS 127.1 ±36.4/134.5 (67.0)
Number of days in PICU/patient 20.4 ±18.4/17.0 (21.5) 23.8 ±18.4/19.0 (26.3) NS 21.9 ±19.9/17.5 (27.0)
Percentage of days of mechanical 
ventilation
95.5 ±16.1/100.0 (0.0) 37.5 ±16.1/32.0 (70.3)  <0.001* 69.0 ±40.7/100.0 (68.0)
Number of VPS at CRRT initiation 1.40 ±0.87/1.00 (1.00) 0.86 ±0.87/1.00 (1.00)   0.039 1.15 ±0.89/1.00 (2.00)
CRP [mg/L] at CRRT initiation 221.9 ±146.0/238.0 (236.8) 111.3 ±146.0/82.0 (149.8)    0.005 171.4 ±135.8/151.0 (215.0)
Total protein [g/L] at CRRT initiation 53.5 ±11.6/53.7 (16.6) 51.0 ±11.6/52.0 (13.0) NS 52.4 ±11.2/53.1 (15.1)
Albumin [g/L] at CRRT initiation 28.5 ±7.5/29.0 (8.9) 27.5 ±7.5/27.0 (12.9) NS 28.1 ±7.4/28.0 (11.2)
eGFR [mL/min/1.73 m2] at CRRT initiation 44.6 ±21.4/45.6 (25.7) 31.7 ±21.4/28.4 (25.8) NS 38.7 ±23.1/34.7 (32.7)
Urea [mmol/L] at CRRT initiation 22.5 ±13.1/17.0 (22.4) 25.9 ±13.1/21.0 (18.3) NS 24.0 ±15.0/20.1 (20.4)
UO [mL/kg/h] at CRRT initiation 0.72 ±0.72/0.40 (0.95) 1.31 ±0.72/1.20 (1.42)   0.048 0.99 ±1.03/0.65 (1.30)
FO% at CRRT initiation 45.0 ±36.1/32.0 (32.0) 24.1 ±36.1/20.0 (27.0)   0.024 35.5 ±31.6/27.3 (32.5)
Day of CRRT initiation 6.6 ±7.9/3.0 (8.3) 4.6 ±7.9/1.0 (5.8)   NS* 5.7 ±6.9/2.0 (8.0)
* Wilcoxon rank-sum test; ** Yates’s modification of the χ2 test; AKI – acute kidney injury; CRP – C-reactive protein; CRRT – continuous renal replacement 
therapy; eGFR – estimated glomerular filtration rate; FO% – fluid overload percentage; Hep-ACG – heparin anticoagulation; MOF – multi-organ failure;  
PICU – pediatric intensive care unit; QC – citrate flow rate; QD – dialyzate flow rate; QS – supplement flow rate; RCA – regional citrate anticoagulation;  
SIMV – synchronized intermittent mandatory ventilation; UO – urine output; VPS – vasopressors; SD – standard deviation; IQR – interquartile range;  
NS – not significant.
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and 4/10  =  0.40, respectively; thus, the mortality OR 
was 1.91/0.40 = 4.8). Nevertheless, the number of VPS em-
ployed at the time of CRRT initiation and the absolute per-
centage of days with VPS administration during the PICU 
stay in the Hep-ACG group were significantly higher than 
in the RCA group (Table 1); thus, it may be concluded that 
the clinical status of the children treated with Hep-ACG 
was generally more severe compared to the RCA group, 
which is a probable reason of the higher mortality. While 
analyzing whether the employed ACG method might pos-
sibly affect the outcome, the multivariable analysis of the 
effect of FO% and the applied ACG mode on the survival 
rate was conducted. The data presented in Table 1 dem-
onstrates that no significant difference was found in FO% 
values in the children dialyzed using the Hep-ACG vs RCA 
methods. On the other hand, as shown by the multivari-
able analysis of the effect of FO% and the applied ACG 
mode on survival rate, the only difference in survival was 
observed in the population of children dialyzed with Hep-
ACG, while in the population of the RCA children, no 
significant difference was seen in mortality (Table 4).
The surviving children required a significantly higher 
Hep dosage, which means that the amount of the admin-
istered Hep was not associated with mortality, while the 
deceased children received a significantly higher citrate 
dosage, despite the fact that their CaT/CaI ratio was main-
tained within the normal range (Table 3).
The mean and median values of FO% of the CRRT chil-
dren since 2009 were high in comparison to the reported 
percentages in the literature.8,9 There was no difference 
in FO% between the periods 2009–2012 and 2013–2016 
(mean ±SD: 35.1 ±34.0 and median (IQR): 25.0 (35.2) vs 
mean ±SD: 35.7 ±30.4 and median (IQR): 28.8 (29.0)). In ad-
dition, there was no difference in the mean (2009–2012: 
5.5 ±5.6 vs 2013–2016: 5.8 ±7.9) and median (2009–2012: 
3.0 (8.0) vs 2013–2016: 2.0 (8.0)) day of CRRT initiation 
during the children’s hospitalization in PICU over the 
analyzed period.
There was no difference in the duration of the PICU 
hospitalization between the CRRT patients (n = 46 (1.4%); 
mean ±SD/median (IQR): 21.9 ±19.9/17.5 (27.0)) and the 
rest of the PICU children hospitalized during the same 
period (n = 3,255; mean ±SD/median (IQR): 25.4 ±26.2/16.0 
(24.0)). However, a significant difference was noted in the 
mortality between the 2 groups of patients (54% vs 6.5%; 
p < 0.001).
Table 3. Univariate analysis of CRRT-associated factors in the deceased and surviving children in the studied population
Variable Deceased, n = 25n [%]
Surviving, n = 21
n [%] p-value
Total, n = 46
n [%]
Patients on Hep-ACG/RCA 21 (84.0)/4 (16.0) 11 (52.4)/10 (47.6)    0.020 32 (69.6)/14 (30.4)
CRRT sessions on Hep-ACG/RCA 73 (56.6)/56 (43.4) 38 (41.8)/53 (58.2)    0.030 111 (50.5)/109 (49.5)
Number of hours of CRRT sessions 
on Hep-ACG/RCA
3,363 (52.2)/3,076 (47.8) 1,800 (42.6)/2,424 (57.4) <0.001 5,163 (48.4)/5,500 (51.6)
Variable mean ±SD/median (IQR) mean ±SD/median (IQR) p-value mean ±SD/median (IQR)
Number of hours of CRRT/patient 257.6 ±319.0/154.0 (258.5) 201.1 ±191.9/144.0 (218.3) NS 231.8 ±267.3/149.0 (222.0)
Filters/patient 5.2 ±5.6/4.0 (3.0) 4.3 ±4.2/2.0 (3.3)   NS* 4.8 ±5.0/3.0 (3.0)
Number of hours of a single filter 
work 
49.9 ±24.2/66.0 (48.0) 46.4 ±26.0/59.0 (50.8)   NS* 48.5 ±25.0/62.0 (48.0)
BFR [mL/min/kg] 2.57 ±1.17/2.40 (1.55) 2.78 ±1.05/2.50 (1.30) NS 2.67 ±1.11/2.50 (1.30)
Dialysis dose: QD+QS (+QC) 
[mL/h/kg]/patient
59.47 ±24.24/50.00 (33.96) 59.87 ±22.62/60.00 (21.73)   NS* 59.63 ±23.56/55.00 (31.85)
UFR [mL/h/kg] 2.62 ±1.63/2.40 (1.95) 2.40 ±1.44/2.10 (2.10)   NS* 2.53 ±1.55/2.30 (2.00)
ACT [s] 147.81 ±44.60/133.63 (47.14) 138.43 ±20.32/136.60 (24.61)   NS* 137.38 ±37.54/132.00 (41.05)
Heparin bolus [mg/kg] at the 
session start 
0.20 ±0.12/0.18 (0.10) 0.21 ±0.10/0.21 (0.09) NS 0.21 ±0.11/0.20 (0.09)
Heparin dose [mg/kg/h] 0.13 ±0.09/0.11 (0.13) 0.17 ±0.10/0.16 (0.08) 0.002* 0.14 ±0.10/0.13 (0.11)
Percentage of calcium 
compensation
73.44 ±22.58/70.00 (30.00) 70.74 ±23.87/78.00 (40.00)   NS* 72.18 ±23.19/75.00 (35.00)
Citrate dose 3.13 ±0.24/3.10 (0.20) 2.98 ±0.26/3.00 (0.30) <0.001* 3.06 ±0.26/3.00 (0.20)
CaT/CaI 1.91 ±0.70/2.08 (0.35) 1.14 ±0.93/1.00 (1.99) <0.001* 1.52 ±0.91/1.95 (1.17)
* Wilcoxon rank-sum test; ACT – activated clotting time; BFR – blood flow rate; CaT/CaI – total calcium/ionic calcium index; CRRT – continuous renal 
replacement therapy; Hep-ACG – heparin anticoagulation; RCA – regional citrate anticoagulation; QC – citrate flow rate; QD – dialyzate flow rate;  
QS – supplement flow rate; UFR – ultrafiltration rate; SD – standard deviation; IQR – interquartile range; NS – not significant.  
Table 4. Multivariable analysis of the impact of fluid overload percentage 
(FO%) and applied anticoagulation (ACG) mode on the survival rate
FO% – deceased FO% – surviving p-value
Hep-ACG 45.9 ±34.5 21.4 ±23.8 0.039
RCA 41.4 ±46.4 27.7 ±16.8 NS
p-value NS NS –
Data presented as mean ± standard deviation (SD). ACG – anticoagulation; 
FO% – fluid overload percentage; RCA – regional citrate anticoagulation; 
NS – not significant.
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Discussion
Continuous renal replacement therapy has become the 
treatment of choice for supporting critically ill patients 
with AKI.17 Using a revised AKI definition, recent stud-
ies have indicated that up to 10% of all children admitted 
to PICUs suffer from some degree of kidney injury.3 In ac-
cordance with the data from the literature, in the present 
study, the highest percentage of patients requiring CRRT 
included children with a primary diagnosis of a hema-
tological/oncological disorder (56.5%) and children co-
diagnosed with MOF (67.4%).
In the literature, several factors have been identified as 
outcome predictors in the pediatric population requiring 
CRRT, including late CRRT initiation, hemodynamic in-
stability, specified VPS number and dosage dependency, 
underlying diseases, low body weight, young age, need for 
mechanical ventilation, presence of MOF, and FO%.5,11,18–25 
In our center, the surviving children required less inten-
sive mechanical respiratory support, were administered 
a lower number of VPS at CRRT initiation, a lower absolute 
percentage of days with VPS administration during their 
PICU stay, and lower CRP values, but they maintained 
a significantly higher UO value on the day of CRRT initia-
tion, which resulted in the degree of their overhydration at 
the initiation of CRRT being almost 2-fold lower on aver-
age. On the other hand, in the population of non-survi-
vors, MOF as the immediate cause of CRRT initiation was 
significantly more common. According to the literature, 
MOF occurs in 30–50% of children in PICUs and is respon-
sible for a higher percentage of total deaths.26,27 In a study 
by Hayes et al., a diagnosis of MOF was significantly as-
sociated with increased mortality, as it was present in 100% 
of non-survivors and in 69% of survivors.22 Although in our 
center no significant differences were observed in the main 
diagnosis as a factor that might affect mortality, apart from 
purely nephrological causes, it was nevertheless demon-
strated that the probability of death in the cases of con-
comitant MOF was almost 6 times higher.
Determining the therapeutic dose for CRRT in criti-
cally ill children remains a challenge. An analysis of a few 
randomized studies comparing a conventional vs intensive 
CRRT dose did not result in any differences in the out-
comes (including kidney function and mortality) of PICU 
patients.8,28 In our center, no significant differences were 
noted in the dialysis dose between the survivors vs non-
survivors, either.
There are numerous studies which prove that higher 
fluid accumulation is an independent risk factor of death 
in CRRT patients even after adjusting for severity of ill-
ness.19,21–23 The majority of studies indicate that a threshold 
of FO% equal to 20% is associated with a large increase 
in mortality.8,9 In  the literature addressing FO% in pe-
diatric CRRT, the average FO% was 16.4% in survivors 
and 34% in non-survivors, and the survival rate was 58% 
in those with FO% <20% as compared to 40% in those with 
FO% >20%, despite comparable illness severity scores.11,25 
According to Sutherland et al., multivariable analysis sug-
gested that each 1% increase in FO% was associated with 
a 3% increase in mortality OR.21 In the current study, the 
mean values of FO% showed significant differences between 
the surviving children (24.1%) and non-survivors (45.0%). 
The cut-off value was assumed as FO% = 25%, which dem-
onstrated that in the group of children with FO% <25%, the 
mortality was significantly more than 2-fold lower than in the 
group of children with FO% ≥25% (33.3% vs 67.9%). A wors-
ening of the prognosis in the latter population of patients 
was also demonstrated by the analysis of the Kaplan-Meier 
curves (Fig. 1). In addition, the univariable logistic regres-
sion analysis, as in the study conducted by Sutherland et al., 
confirmed that each increase in FO% by 1% increased the 
mortality OR by 3%.21
In the current literature there are studies evaluating the 
efficacy and safety of RCA vs Hep-ACG in pediatric CRRT. 
These studies have shown that RCA is effective, provides 
equivalent circuit survival and decreases bleeding as com-
pared to Hep-ACG.29 In the studied population, treatment 
sessions were generally well tolerated by all patients.
Furthermore, in the literature, there are both studies re-
porting that there is no significant difference in mortality 
between the RCA (41.3%) and Hep-ACG (42.7%) groups, and 
studies, such as the one by Oudemans-van Straaten et al., 
proving that RCA appears particularly beneficial, especial-
ly after surgery, in sepsis and MOF (suggesting an interfer-
ence with inflammation), reducing the overall probability 
of death.13,30–32
Although the data collected in  our center suggests 
that the mortality in children dialyzed with Hep-ACG 
is more than 2-fold higher than the mortality while using 
the RCA mode, one should take into consideration the 
fact that the clinical status of children treated with Hep-
ACG was in general more severe than the clinical status of 
Fig. 1. Comparative Kaplan-Meier analysis for the probability of survival 
of the continuous renal replacement therapy (CRRT) patients depending 
on fluid overload percentage (FO%). The cut-off value of 25% was 
statistically significant (Mantel-Cox test: p = 0.012)
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the RCA group, which is undoubtedly the reason of their 
higher mortality. However, subsequent analyses comparing 
Hep-ACG with RCA in detail demonstrated that a sig-
nificant effect on the outcome depending on the values 
of FO% occurred only in the group of children dialyzed 
using Hep-ACG.
A crucial factor in the discrepancy between the mortality 
of patients treated with the particular modes of ACG might 
be the fact that RCA in our center has been practically used 
only since the beginning of 2015, and that since that time 
virtually all (14/15) CRRT sessions were performed using 
this mode of ACG, which means that patients qualified to 
CRRT during that time were in a better general condition, 
which may reflect higher vigilance and awareness of the 
medical staff about the need for CRRT implementation 
in PICU patients, as well as better acquaintance with the 
CRRT technique itself.
In our center, CRRT is prescribed and handled by the 
nephrologists in collaboration with the PICU team. Nev-
ertheless, since the onset of this technique in our cen-
ter (2009), we have not observed a decrease in the degree 
of FO% or a significant difference in the day of initiation 
of this renal replacement mode.
According to  the literature, mortality in  PICU pa-
tients with secondary AKI requiring CRRT is high, be-
ing estimated at 35.6–60%; CRRT is required by about 
5% of  all PICU patients.4,18,19,21,22,24,25,33 Children with 
AKI at the time of admission are hospitalized twice as 
long as patients with normal renal function, while those 
who develop AKI during the PICU course have a 4-fold 
increase in the length of stay.3 In our center, in the pe-
riod 2009–2016, contrary to the data from the literature 
on the subject, the duration of PICU hospitalization did 
not significantly differ between the children who did and 
did not require CRRT, but the mortality in the former 
group was more than 8-fold higher, which confirmed the 
reports from the literature describing a poorer prognosis 
in those patients.9
The authors are cognizant of some limitations of the 
study, as it was a retrospective, observational, single-center 
study, where interventions could not be standardized. Nev-
ertheless, in the present study, a detailed analysis was per-
formed of the course of PICU hospitalization of all 46 chil-
dren who were subjected to this treatment technique since 
the onset of CRRT use in the center. In order to achieve 
the maximum homogeneity of the analyzed population, 
in view of the differing nature of AKI in such patients, the 
analysis did not include patients hospitalized in the cardiac 
surgery intensive care unit. The study provided a detailed 
characterization of practically all the factors that might 
affect the outcome in this population of patients, which 
is of high importance for future improvements in the qual-
ity of care of such patients.
Conclusions
The  mortality of  PICU patients who require CRRT 
is more than 8-fold higher than the mortality of the to-
tal PICU population. Coexisting MOF as the immediate 
cause of CRRT introduction increases the mortality almost 
6 times. Apart from the patients’ general clinical condi-
tion (which is reflected by the CRP values and the need 
for mechanical ventilation), only FO% exerts a significant 
negative effect on the survival of patients requiring CRRT. 
The mortality of children whose FO% at the time of CRRT 
initiation equals or exceeds 25% is almost 2-fold higher 
than the mortality of children whose FO% at the time 
of CRRT initiation does not exceed this value.
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